Propanc Biopharma, Inc.: Form 10-Q for the period ended Dec 31, 2017
Filed with the SEC on Feb 9, 2018 and accepted by EDGAR at Feb 8, 2018, 20:58 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2017-10-01 to 2017-12-31 | $1.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2017-07-01 to 2017-12-31 | $1.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2017-10-01 to 2017-12-31 | −$1.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2017-07-01 to 2017-12-31 | −$2.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2017-10-01 to 2017-12-31 | $486.8k | us-gaap:InterestExpense |
| Interest expense | 6 months2017-07-01 to 2017-12-31 | $1.4m | us-gaap:InterestExpense |
| Income tax | 3 months2017-10-01 to 2017-12-31 | −$180.3k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2017-07-01 to 2017-12-31 | −$180.3k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-10-01 to 2017-12-31 | −$2.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months2017-07-01 to 2017-12-31 | −$4.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-10-01 to 2017-12-31 | −$0.20 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2017-07-01 to 2017-12-31 | −$0.49 | us-gaap:EarningsPerShareBasicAndDiluted |
| Cash and equivalents | At period end2017-12-31 | $112.5k | us-gaap:Cash |
| Current assets | At period end2017-12-31 | $116.9k | us-gaap:AssetsCurrent |
| Total assets | At period end2017-12-31 | $129.1k | us-gaap:Assets |
| Current liabilities | At period end2017-12-31 | $7.3m | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2017-12-31 | $4.4m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2017-12-31 | −$7.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-18-001696. Last ingested by Listed: Oct 29, 2026, 17:01 ET. Listed shows no prices and gives no investment advice.